Interferon gamma human recombinant - Pharmaclon

Drug Profile

Interferon gamma human recombinant - Pharmaclon

Alternative Names: Ingaron

Latest Information Update: 16 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pharmaclon
  • Class Antineoplastics; Interferons; Lymphokines
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer; Chlamydial infections; Chronic granulomatous disease; Genital warts; Hepatitis B; Hepatitis C; Herpes zoster; Herpesvirus infections; HIV infections; Prostatitis; Tuberculosis

Most Recent Events

  • 04 Jun 2015 Efficacy and adverse events data from clinical trials in Herpes infection released by Pharmaclon before June 2015
  • 04 Jun 2015 Efficacy and adverse events data from clinical trials in Chlamydial infections released by Pharmaclon before June 2015
  • 04 Jun 2015 Efficacy data from clinical trials in Tuberculosis released by Pharmaclon before June 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top